LCTXLineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, a…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript CEO outlines manufacturing scale-up strategy for cell therapies amid $50.8M cash runway. | ||
 Lineage Cell Therapeutics Q2 Earnings Call Highlights Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type 1 diabetes and hearing loss programs while Roche and Genentech continue surgical-delivery optimiza | ||
 Lineage Cell Therapeutics, Inc. Q2 2026 Earnings Call Summary Moby summary of Lineage Cell Therapeutics, Inc.'s Q2 2026 earnings call | ||
Lineage Cell Therapeutics Inc (LCTX) (Q2 2026) Earnings Call Highlights: Cash Runway Extended, ... Lineage Cell Therapeutics Inc (LCTX) reports net income of $1.5 million, extends cash runway into Q3 2028, and advances key pipeline programs despite revenue decline. | ||
 Lineage Cell (LCTX) Reports Q2 Loss, Lags Revenue Estimates Lineage Cell (LCTX) delivered earnings and revenue surprises of 0.00% and -80.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject’ Cell Therapy Plan Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) used a conference call to outline its manufacturing strategy and development plans for COR1, a wholly owned preclinical cell transplant program being developed as a potential treatment for corneal endothelial disease. Chief Executive Officer Brian Culle | ||